EE200100382A - Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod - Google Patents

Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod

Info

Publication number: EE200100382A
Authority: EE; Estonia
Prior art keywords: cyclodextrin; ras; hydroxypropyl; complex; preparation
Prior art date: 1999-01-21

Application number

EEP200100382A

Other languages

English (en)

Estonian (et)

Inventor

S. Raghavan Krishnaswamy

M. Malloy Timothy

A. Varia Sailesh

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-21

Filing date

1999-12-21

Publication date

2002-12-16

1999-12-21 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2002-12-16 Publication of EE200100382A publication Critical patent/EE200100382A/xx

Links

229920000858 Cyclodextrin Polymers 0.000 title 1
239000001116 FEMA 4028 Substances 0.000 title 1
229940124226 Farnesyltransferase inhibitor Drugs 0.000 title 1
229960004853 betadex Drugs 0.000 title 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
-1 sulfobutyl Chemical group 0.000 title 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nanotechnology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Plural Heterocyclic Compounds (AREA)

EEP200100382A 1999-01-21 1999-12-21 Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod EE200100382A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11664799P	1999-01-21	1999-01-21
PCT/US1999/030424 WO2000042849A1 (en)	1999-01-21	1999-12-21	COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number	Publication Date
EE200100382A true EE200100382A (et)	2002-12-16

Family

ID=22368422

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100382A EE200100382A (et)	1999-01-21	1999-12-21	Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod

Country Status (33)

Country	Link
US (1)	US6218375B1 (id)
EP (1)	EP1143796A4 (id)
JP (1)	JP2002535253A (id)
KR (1)	KR100708360B1 (id)
CN (1)	CN1219517C (id)
AR (1)	AR022323A1 (id)
AU (1)	AU772204B2 (id)
BG (1)	BG105666A (id)
BR (1)	BR9916566A (id)
CA (1)	CA2359646C (id)
CO (1)	CO5160253A1 (id)
CZ (1)	CZ20012601A3 (id)
EE (1)	EE200100382A (id)
GE (1)	GEP20043214B (id)
HK (1)	HK1038865A1 (id)
HU (1)	HUP0105160A3 (id)
ID (1)	ID30139A (id)
IL (1)	IL144025A (id)
LT (1)	LT4893B (id)
LV (1)	LV12712B (id)
MY (1)	MY119700A (id)
NO (1)	NO20013585L (id)
NZ (1)	NZ511995A (id)
PE (1)	PE20001419A1 (id)
PL (1)	PL195280B1 (id)
RU (1)	RU2230062C2 (id)
SK (1)	SK9602001A3 (id)
TR (1)	TR200102109T2 (id)
TW (1)	TWI232752B (id)
UA (1)	UA67825C2 (id)
UY (2)	UY25987A1 (id)
WO (1)	WO2000042849A1 (id)
ZA (1)	ZA200104416B (id)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) *	2001-06-13	2003-03-05	Otsuka Pharmaceut Factory Inc	注射用シロスタゾール水性製剤
US6566347B1 (en) *	2001-08-22	2003-05-20	Duquesne University Of The Holy Ghost	Controlled release pharmaceutical
WO2003041658A2 (en) *	2001-11-13	2003-05-22	Bristol-Myers Squibb Company	Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
KR100451485B1 (ko)	2002-03-28	2004-10-06	주식회사종근당	푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) *	2002-05-04	2005-03-22	Cydex, Inc.	Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) *	2002-05-28	2004-11-16	Taisho Pharmaceutical Co., Ltd.	Pharmaceutical composition
US20040009972A1 (en) *	2002-06-17	2004-01-15	Ding Charles Z.	Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7157446B2 (en) *	2003-05-02	2007-01-02	Bristol Myers Squibb Company	Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0616447A2 (pt) *	2005-09-30	2011-06-21	Ovation Pharmaceuticals Inc	complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo
US20100204178A1 (en)	2006-10-02	2010-08-12	James Cloyd	Novel parenteral carbamazepine formulation
CN100503647C (zh) *	2005-11-02	2009-06-24	南京师范大学	羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) *	2006-03-31	2008-02-01	Alcon Mfg Ltd	Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
PL2094308T3 (pl) *	2006-11-21	2011-06-30	Novartis Ag	Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
US12370352B2 (en)	2007-06-28	2025-07-29	Cydex Pharmaceuticals, Inc.	Nasal and ophthalmic delivery of aqueous corticosteroid solutions
MY169791A (en)	2008-10-22	2019-05-15	Array Biopharma Inc	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
MX338405B (es)	2010-05-26	2016-04-14	Neurophyxia B V	Formulaciones de 2-iminobiotina y sus usos.
WO2012034038A2 (en)	2010-09-09	2012-03-15	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
ES2642843T3 (es) *	2011-10-07	2017-11-20	Pisces Therapeutics Llc	Tratamiento de enfermedad maligna y no maligna con antagonistas de Ras
CN105194685A (zh) *	2015-10-15	2015-12-30	重庆大学	磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
EP3389653B1 (en)	2015-12-16	2023-11-08	Neurophyxia B.V.	2-iminobiotin for use in the treatment of brain cell injury
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
FI3439662T3 (fi)	2016-04-04	2024-09-04	Loxo Oncology Inc	(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (en)	2016-05-18	2020-11-25	Loxo Oncology Inc.	Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) *	2019-11-15	2021-05-20	Cyclolab Cyclodextrin Research And Development Laboratory Ltd.	Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
JP7850663B2 (ja)	2019-12-27	2026-04-23	ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド	スピロ環含有キナゾリン化合物
MX2024007452A (es) *	2021-12-15	2024-07-09	Sillajen Inc	Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en)	2023-10-12	2026-04-09	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
TW202547461A (zh)	2024-05-17	2025-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5630927A (en) *	1979-08-24	1981-03-28	Zeria Shinyaku Kogyo Kk	Stabilization of guaiazulene and its derivative
US4371673A (en) *	1980-07-21	1983-02-01	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Water soluble forms of retinoids
US4727064A (en) *	1984-04-25	1988-02-23	The United States Of America As Represented By The Department Of Health And Human Services	Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) *	1984-04-25	1986-06-24	The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services	Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH07165616A (ja) *	1993-12-09	1995-06-27	Hisamitsu Pharmaceut Co Inc	シクロデキストリンの複合組成物及び複合化法
US6011029A (en) *	1996-02-26	2000-01-04	Bristol-Myers Squibb Company	Inhibitors of farnesyl protein transferase
JPH1067639A (ja) *	1996-08-26	1998-03-10	Shiseido Co Ltd	ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

1999
- 1999-12-21 KR KR1020017009131A patent/KR100708360B1/ko not_active Expired - Fee Related
- 1999-12-21 IL IL14402599A patent/IL144025A/en not_active IP Right Cessation
- 1999-12-21 CZ CZ20012601A patent/CZ20012601A3/cs unknown
- 1999-12-21 ID IDW00200101596A patent/ID30139A/id unknown
- 1999-12-21 EE EEP200100382A patent/EE200100382A/xx unknown
- 1999-12-21 HU HU0105160A patent/HUP0105160A3/hu unknown
- 1999-12-21 BR BR9916566-0A patent/BR9916566A/pt not_active Application Discontinuation
- 1999-12-21 RU RU2001118265/04A patent/RU2230062C2/ru not_active IP Right Cessation
- 1999-12-21 CA CA002359646A patent/CA2359646C/en not_active Expired - Fee Related
- 1999-12-21 HK HK02100115.8A patent/HK1038865A1/zh unknown
- 1999-12-21 NZ NZ511995A patent/NZ511995A/en unknown
- 1999-12-21 TR TR2001/02109T patent/TR200102109T2/xx unknown
- 1999-12-21 JP JP2000594323A patent/JP2002535253A/ja active Pending
- 1999-12-21 GE GEAP19995955A patent/GEP20043214B/en unknown
- 1999-12-21 UA UA2001085843A patent/UA67825C2/uk unknown
- 1999-12-21 AU AU23740/00A patent/AU772204B2/en not_active Ceased
- 1999-12-21 EP EP99967470A patent/EP1143796A4/en not_active Withdrawn
- 1999-12-21 PL PL99366338A patent/PL195280B1/pl not_active IP Right Cessation
- 1999-12-21 SK SK960-2001A patent/SK9602001A3/sk unknown
- 1999-12-21 CN CNB998157074A patent/CN1219517C/zh not_active Expired - Fee Related
- 1999-12-21 WO PCT/US1999/030424 patent/WO2000042849A1/en not_active Ceased
- 1999-12-31 MY MYPI99005834A patent/MY119700A/en unknown
2000
- 2000-01-14 TW TW089100557A patent/TWI232752B/zh not_active IP Right Cessation
- 2000-01-17 US US09/483,840 patent/US6218375B1/en not_active Expired - Lifetime
- 2000-01-18 CO CO00002434A patent/CO5160253A1/es unknown
- 2000-01-20 AR ARP000100255A patent/AR022323A1/es unknown
- 2000-01-21 UY UY25987A patent/UY25987A1/es not_active Application Discontinuation
- 2000-01-21 PE PE2000000046A patent/PE20001419A1/es not_active Application Discontinuation
- 2000-01-21 UY UY25986A patent/UY25986A1/es unknown
2001
- 2001-05-29 ZA ZA200104416A patent/ZA200104416B/en unknown
- 2001-06-21 LT LT2001064A patent/LT4893B/lt not_active IP Right Cessation
- 2001-07-03 BG BG105666A patent/BG105666A/xx unknown
- 2001-07-04 LV LVP-01-101A patent/LV12712B/en unknown
- 2001-07-20 NO NO20013585A patent/NO20013585L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UY25987A1 (es)	2000-09-29
ID30139A (id)	2001-11-08
AU2374000A (en)	2000-08-07
CN1219517C (zh)	2005-09-21
NO20013585L (no)	2001-09-04
BG105666A (en)	2002-04-30
NO20013585D0 (no)	2001-07-20
KR20010101611A (ko)	2001-11-14
AR022323A1 (es)	2002-09-04
HUP0105160A2 (hu)	2002-05-29
RU2230062C2 (ru)	2004-06-10
MY119700A (en)	2005-06-30
EP1143796A1 (en)	2001-10-17
PL366338A1 (en)	2005-01-24
WO2000042849A1 (en)	2000-07-27
CZ20012601A3 (cs)	2002-05-15
LT2001064A (en)	2001-10-25
UY25986A1 (es)	2000-09-29
PE20001419A1 (es)	2001-02-21
LV12712B (en)	2002-01-20
JP2002535253A (ja)	2002-10-22
UA67825C2 (uk)	2004-07-15
ZA200104416B (en)	2002-05-29
IL144025A0 (en)	2002-04-21
LV12712A (lv)	2001-09-20
US6218375B1 (en)	2001-04-17
HUP0105160A3 (en)	2003-01-28
BR9916566A (pt)	2001-11-13
CA2359646C (en)	2008-12-02
CO5160253A1 (es)	2002-05-30
LT4893B (lt)	2002-02-25
TWI232752B (en)	2005-05-21
IL144025A (en)	2004-05-12
SK9602001A3 (en)	2002-06-04
HK1038865A1 (zh)	2002-04-04
KR100708360B1 (ko)	2007-04-17
GEP20043214B (en)	2004-04-26
CA2359646A1 (en)	2000-07-27
PL195280B1 (pl)	2007-08-31
EP1143796A4 (en)	2002-03-20
TR200102109T2 (tr)	2001-12-21
NZ511995A (en)	2003-11-28
CN1333651A (zh)	2002-01-30
AU772204B2 (en)	2004-04-22

Publication	Publication Date	Title
EE200100382A (et)	2002-12-16	Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod
NO20020635L (no)	2002-03-15	Hemmere av proteinpolymeriserings og metodene som brukes
EP1410397A4 (en)	2007-08-29	NANOTUBE FILMS AND ARTICLES
DE60024972D1 (de)	2006-01-26	Wiederbeschreibbare cd und deren herstellungsverfahren
ID26848A (id)	2001-02-15	Koupling untuk gigi-gigi eksapator dan sejenisnya
NO20021587L (no)	2002-04-04	Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
IS6054A (is)	2001-08-17	Oxamsýrur og afleiður sem skjaldkirtilsviðtakabindlar
AU2001284695A1 (en)	2002-02-13	Methods and compositions for the repair and/or regeneration of damaged myocardium
NO20015004L (no)	2001-10-15	Vandig desinfiseringsmiddel og sammensetning for vask av harde overflater samt fremgangsmåte for anvendelse derav
FI990324L (fi)	2000-08-17	Polymeerikalvo ja menetelmä sen valmistamiseksi
NO20021736D0 (no)	2002-04-12	Nytt preparat og fremgangsmåte for stabilisering av det
ID28752A (id)	2001-06-28	Metode-metode dan komposisi-komposisi sanitasi
NO20005017D0 (no)	2000-10-05	Metoder og viskøse sammensetninger for behandling av brønner
NO20005219D0 (no)	2000-10-17	FremgangsmÕte for bedring av ytelsen til fiske- og bore- slagrør i avviks- og høyavviks borehull
NO20015542L (no)	2002-01-14	Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
FI20011671A0 (fi)	2001-08-20	Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
NO20012963D0 (no)	2001-06-15	Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
FI20000292A0 (fi)	2000-02-11	Testausjärjestely ja testausmenetelmä
NO20005763L (no)	2001-01-10	DHEA-sammensetning og fremgangsmåte
FI980269L (fi)	1999-08-07	Menetelmä norborneenin ja sen johdannaisten syntetisoimiseksi
FI19992095L (fi)	2001-03-29	Menetelmä ja entsyymivalmiste prosessiteollisuuteen
EE200100305A (et)	2002-08-15	Preparaat, selle kasutamine ja valmistamismeetod
FI20002396L (fi)	2002-05-01	Linearisointimenetelmä ja vahvistinjärjestely
NO20021270L (no)	2002-03-14	Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner
FI20011722A0 (fi)	2001-08-28	Menetelmä tärkkelyksen modifioimiseksi, tärkkelys ja sen käyttö